Kristi Rosa

Encorafenib plus cetuximab and FOLFIRI significantly improved response vs standard therapy in first-line BRAF V600E–mutant metastatic colorectal cancer.

The FDA has approved narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Interim phase 2 data show nab-sirolimus plus letrozole produced an ORR of 41% and 13.6-month PFS with manageable safety in endometrioid endometrial cancer.

Ten-year data from the PORTEC-3 trial show that adjuvant chemoradiotherapy improves OS and RFS vs radiotherapy alone in high-risk endometrial cancer.

Only 13% of US patients with CP-CML received FDA-recommended ponatinib dosing, highlighting gaps in dose optimization and the need for education.

Safety analysis shows sacituzumab govitecan plus pembrolizumab has a manageable profile and fewer dose reductions than chemoimmunotherapy in PD-L1+ TNBC.

Epcoritamab plus R-CHOP delivered durable remissions beyond 3 years across high-risk subgroups of patients with newly diagnosed DLBCL.

The FDA has granted regular approval to rucaparib (Rubraca) for BRCA mutation–associated metastatic castration-resistant prostate cancer.

Sacituzumab govitecan showed manageable safety vs chemotherapy in first-line TNBC, with fewer dose changes and faster AE resolution.

The FDA approved T-DXd plus pertuzumab for the first-line treatment of unresectable or metastatic HER2-positive breast cancer.

Bezuclastinib markedly improved symptoms and disease markers in nonadvanced systemic mastocytosis, showing durable benefit and a manageable safety profile.

The FDA has approved niraparib and abiraterone acetate with prednisone for BRCA2-mutated mCSPC.

Gedatolisib regimens showed PFS benefits irrespective of prior treatment duration in HR-positive, HER2-negative PIK3CA wild-type advanced breast cancer.

Zanubrutinib shows sustained 6-year efficacy and safety in treatment-naive CLL/SLL, outperforming BR with durable PFS and high response rates.

The SAVE regimen shows high response and MRD negativity rates in patients with AML, but myelosuppression and infectious complications remain key concerns.

Elranatamab plus iberdomide showed a 95.5% response rate in patients with BCMA-naive relapsed/refractory myeloma per early MagnetisMM-30 data.

Cretostimogene grenadenorepvec shows durable activity in BCG-unresponsive papillary-only NMIBC with no progression to MIBC and favorable tolerability.

Rucaparib delivers consistent rPFS benefits across all age groups in BRCA-mutated mCRPC, reinforcing its role as an effective treatment option.

Adjuvant pembrolizumab delivers sustained clinical benefits across ccRCC subgroups with no new long-term safety signals.

Tovorafenib produced deep, durable responses in pLGG, with long treatment-free intervals and minimal tumor rebound after therapy.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in November 2025 spanning tumor types.

Phase 2 study finds 177Lu-Dotatate safe in advanced intracranial meningioma, with a 6-month PFS rate surpassing historical benchmarks.

Long-term ReNeu results showed deeper, more durable responses to mirdametinib in NF1-PN with extended treatment in both adults and children.

The FDA OKs the Oncomine Dx Target Test to identify patients with HER2 TKD–mutant NSCLC eligible for sevabertinib, enabling targeted treatment selection.

Mecbotamab vedotin showed promising survival gains and manageable safety in treatment-refractory soft tissue sarcomas.

The FDA has granted traditional approval to tarlatamab-dlle (Imdelltra) for the treatment of select patients with ES-SCLC.

Cemiplimab wins EU approval after C-POST shows DFS gains for high-risk CSCC, marking the first effective adjuvant immunotherapy option.

Gedatolisib’s NDA filing to the FDA is supported by VIKTORIA-1 data showing marked PFS improvements in HR+/HER2– advanced breast cancer.

Tafasitamab plus lenalidomide/rituximab cut progression risk by over 50% in relapsed follicular lymphoma, supporting its approval as a key second-line option.

Zanidatamab-based regimens improved PFS and OS vs chemotherapy in HER2+ gastroesophageal adenocarcinoma, positioning the agent as a potential new standard.